Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Takayasu, Kurata"'
Autor:
Akihiro Yoshimura, Takayuki Takeda, Nobutaka Kataoka, Keiko Tanimura, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Kentaro Nakanishi, Yuta Yamanaka, Nobuyo Tamiya, Ryoichi Honda, Naoko Okura, Takahiro Yamada, Kiyoaki Uryu, Junji Murai, Shinsuke Shiotsu, Hiroshige Yoshioka, Tadaaki Yamada, Takayasu Kurata, Koichi Takayama
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe efficacy of second-line immune checkpoint inhibitor (ICI) therapy is limited in non-small cell lung cancer (NSCLC) patients with ≤ 49% PD-L1 expression. Although chemoimmunotherapy is a promising strategy, platinum-based chemotherap
Externí odkaz:
https://doaj.org/article/8d57729f3fdc4dbb893f9ca297d30e84
Autor:
Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, Kenichi Koyama, Shunsuke Teraoka, Hidenobu Ishii, Kayoko Kibata, Yuichi Ozawa, Takaaki Tokito, Jun Oyanagi, Toshio Shimokawa, Takayasu Kurata, Nobuyuki Yamamoto, Hiroshi Tanaka
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety
Externí odkaz:
https://doaj.org/article/0a4f9483315c4d2c9b33bcff9557a97f
Autor:
Hidenobu Ishii, Koichi Azuma, Takayuki Shimose, Hiroshige Yoshioka, Takayasu Kurata, Naoki Shingu, Masaki Okamoto, Yosuke Kawashima, Isamu Okamoto
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 105-107 (2023)
Abstract Background Recently, the addition of antiprogrammed cell death‐ligand 1 (PD‐L1) monoclonal antibodies, including durvalumab and atezolizumab to platinum‐based chemotherapy, has demonstrated clinical benefits in patients with untreated
Externí odkaz:
https://doaj.org/article/4d675f91827b44ba91532c386bfc766c
Autor:
Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100514- (2023)
Introduction: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for
Externí odkaz:
https://doaj.org/article/4876c2feeaf34060b78e84539b872f0e
Autor:
Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100508- (2023)
Introduction: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan. Methods:
Externí odkaz:
https://doaj.org/article/bcbe60e4a4f34c35855ba34ee7b7698a
Autor:
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Tadaaki Yamada, Nobuyo Tamiya, Naoko Okura, Takahiro Yamada, Junji Murai, Shinsuke Shiotsu, Takayasu Kurata, Koichi Takayama
Publikováno v:
Cancers, Vol 15, Iss 20, p 4988 (2023)
Background: The long overall survival (OS) observed among patients with non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression in chemoimmunotherapy (CIT) groups in previous phase III trials suggests the limited eff
Externí odkaz:
https://doaj.org/article/838cc0c503c947a8babc3b791cc8a615
Autor:
Toshihiko Kaneda, Takayasu Kurata, Tomoko Yoshida, Kayoko Kibata, Hiroshige Yoshioka, Hiroaki Yanagimoto, Kazuhiko Takeda, Takao Yoshida, Koji Tsuta
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibod
Externí odkaz:
https://doaj.org/article/42a2cfeec3fa448fb601a19458098818
Autor:
Tatsuki Ikoma, Toshihiko Matsumoto, Shogen Boku, Tomoyo Yasuda, Masataka Masuda, Takashi Ito, Koh Nakamaru, So Yamaki, Shinji Nakayama, Daisuke Hashimoto, Tomohisa Yamamoto, Nobuhiro Shibata, Tsukasa Ikeura, Makoto Naganuma, Sohei Satoi, Takayasu Kurata
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 10, p 3477 (2023)
Although nanoliposomal irinotecan combined with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) has been used to treat first-line resistant unresectable pancreatic cancer, the efficacy and safety data among the elderly remain limited. We retrospectiv
Externí odkaz:
https://doaj.org/article/9a456deac58042d1916331d75cb75ec1
Autor:
Takayuki Takeda, Tadaaki Yamada, Yusuke Kunimatsu, Keiko Tanimura, Kenji Morimoto, Shinsuke Shiotsu, Yusuke Chihara, Asuka Okada, Shigeto Horiuchi, Makoto Hibino, Kiyoaki Uryu, Ryoichi Honda, Yuta Yamanaka, Hiroshige Yoshioka, Takayasu Kurata, Koichi Takayama
Publikováno v:
Cancers, Vol 15, Iss 5, p 1543 (2023)
Chemoimmunotherapy improved overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in two phase III trials. They set the age-stratified subgroup analyses at 65 years; however, over
Externí odkaz:
https://doaj.org/article/0252b498983540b9a726c20930e5af38
Autor:
Tomohito Saito, MD, PhD, Mistuaki Ishida, MD, PhD, Makiko Kusabe, MD, Takahiro Utsumi, MD, Natsumi Maru, MD, Hiroshi Matsui, MD, Yohei Taniguchi, MD, PhD, Takayasu Kurata, MD, PhD, Hiroaki Kurokawa, MD, PhD, Takanobu Imada, MD, PhD, Koji Tsuta, MD, PhD, Hiroyasu Tsukaguchi, MD, PhD, Tomohiro Murakawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 8, Pp 100204- (2021)
Hypercalcemia is a common electrolyte abnormality in malignancy and is largely caused by activation of parathyroid hormone (PTH) pathways. We report the case of a 76-year-old man with hypercalcemia primarily owing to 1,25-dihydroxyvitamin D3 overprod
Externí odkaz:
https://doaj.org/article/d745569c598847058fdb27c15b1b70b6